Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 7:19:83-91.
doi: 10.2147/OPTH.S480668. eCollection 2025.

Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye

Andrea Bedei  1 , Pedro Rocha Cabrera  2 , Luis Oliveira  3 , Laura Castellini  1 , Giulia De Grazia  4 , Stefano Remiddi  4
Affiliations

Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye

Andrea Bedei et al. Clin Ophthalmol. .

Abstract

Purpose: To assess the efficacy, adherence, and tolerability of a new artificial tear based on arabinogalactan, hyaluronic acid, and trehalose in a population with dry eye disease (DED).

Methods: A retrospective, real-world, post-marketing study identified 96 adult patients (aged 18-80 years) with signs and symptoms of dry eye. These patients received fixed combination therapy with eye drops containing arabinogalactan, hyaluronic acid, and trehalose at various dosing schedules. The data for this study were collected from April 2022 to June 2023. Patients underwent evaluation at baseline (T0) and after a follow-up period of two-three months (T1) using a patient-reported questionnaire.

Results: In 96 adult patients (71 women and 25 men) with dry eye due to various conditions, the results indicated a 98% positive response to therapy. This response included improvements in vision (13%), comfort (39%), redness (13%), itching (16%), photophobia (4%), and tearing (14%). Additionally, 61% of the patients experienced 1-2 hours of comfort following instillation.

Conclusion: This real-life post-marketing study demonstrated clinical improvement of signs and symptoms in patients with dry eye disease using a new artificial tear medical device based on arabinogalactan, hyaluronic acid, and trehalose.

Keywords: arabinogalactan; dry eye; hyaluronic acid; post-marketing study; real-world study; trehalose.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest that could have influenced the work reported in this paper.

Figures

Figure 1
Figure 1
Treatment Questionnaire.
Figure 2
Figure 2
Clinical conditions at baseline.
Figure 3
Figure 3
Prescribed dosing schedule.
Figure 4
Figure 4
Utilization for other reasons.
Figure 5
Figure 5
Positive response to the therapy.
Figure 6
Figure 6
Improvement of the patient’s quality of life.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Smith RE. The tear film complex: pathogenesis and emerging therapies for dry eyes. Cornea. 2005;24(1):1–7. doi:10.1097/01.ico.0000141486.56931.9b - DOI - PubMed
    1. Baudouin C, Irkec M, Messmer EM, et al. Impact of inflammation in dry eye disease: proceedings of ODISSEY group meeting. Acta Ophthalmol. 2018;96(2):111–119. doi:10.1111/aos.13436 - DOI - PMC - PubMed
    1. Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II sex, gender and hormones report. Ocul Surf. 2017;15(3):284–333. doi:10.1016/j.jtos.2017.04.001 - DOI - PubMed
    1. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539–574. doi:10.1016/j.jtos.2017.05.001 - DOI - PubMed
    1. Dion C, Chappuis E, Rippol C. Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials. Nutr Metabol. 2016;12:13–28. - PMC - PubMed

LinkOut - more resources